-DOCSTART- -X- O
The -X- _ O
robustness -X- _ O
of -X- _ O
immune -X- _ O
responses -X- _ O
to -X- _ O
an -X- _ O
antigen -X- _ O
could -X- _ O
be -X- _ O
dictated -X- _ O
by -X- _ O
the -X- _ O
route -X- _ O
of -X- _ O
vaccine -X- _ O
inoculation. -X- _ O
Traditional -X- _ O
smallpox -X- _ O
vaccines -X- _ O
, -X- _ O
essentially -X- _ O
vaccinia -X- _ O
virus -X- _ O
strains -X- _ O
, -X- _ O
that -X- _ O
were -X- _ O
used -X- _ O
in -X- _ O
the -X- _ O
eradication -X- _ O
of -X- _ O
smallpox -X- _ O
were -X- _ O
administered -X- _ O
by -X- _ O
percutaneous -X- _ O
inoculation -X- _ O
( -X- _ O
skin -X- _ O
scarification -X- _ O
) -X- _ O
. -X- _ O
The -X- _ O
modified -X- _ O
vaccinia -X- _ O
virus -X- _ O
Ankara -X- _ O
is -X- _ O
licensed -X- _ O
as -X- _ O
a -X- _ O
smallpox -X- _ O
vaccine -X- _ O
in -X- _ O
Europe -X- _ O
and -X- _ O
Canada -X- _ O
and -X- _ O
currently -X- _ O
undergoing -X- _ O
clinical -X- _ O
development -X- _ O
in -X- _ O
the -X- _ O
United -X- _ O
States. -X- _ O
MVA -X- _ O
is -X- _ O
also -X- _ O
being -X- _ O
investigated -X- _ O
as -X- _ O
a -X- _ O
vector -X- _ O
for -X- _ O
the -X- _ O
delivery -X- _ O
of -X- _ O
heterologous -X- _ O
genes -X- _ O
for -X- _ O
prophylactic -X- _ O
or -X- _ O
therapeutic -X- _ O
immunization. -X- _ O
Since -X- _ O
MVA -X- _ O
is -X- _ O
replication-deficient -X- _ O
, -X- _ O
MVA -X- _ B-Intervention
and -X- _ I-Intervention
MVA-vectored -X- _ I-Intervention
vaccines -X- _ I-Intervention
are -X- _ O
often -X- _ O
inoculated -X- _ O
through -X- _ O
the -X- _ O
intramuscular -X- _ B-Comparison
, -X- _ I-Comparison
intradermal -X- _ I-Comparison
or -X- _ I-Comparison
subcutaneous -X- _ I-Comparison
routes. -X- _ I-Comparison
Vaccine -X- _ O
inoculation -X- _ O
via -X- _ O
the -X- _ O
intramuscular -X- _ B-Comparison
, -X- _ I-Comparison
intradermal -X- _ I-Comparison
or -X- _ I-Comparison
subcutaneous -X- _ I-Comparison
routes -X- _ I-Comparison
requires -X- _ O
the -X- _ O
use -X- _ O
of -X- _ O
injection -X- _ O
needles -X- _ O
, -X- _ O
and -X- _ O
an -X- _ O
estimated -X- _ O
10 -X- _ O
to -X- _ O
20 -X- _ O
% -X- _ O
of -X- _ O
the -X- _ O
population -X- _ O
of -X- _ O
the -X- _ O
United -X- _ O
States -X- _ O
has -X- _ O
needle -X- _ O
phobia. -X- _ O
Following -X- _ O
an -X- _ O
observation -X- _ O
in -X- _ O
our -X- _ O
laboratory -X- _ O
that -X- _ O
a -X- _ O
replication-deficient -X- _ O
recombinant -X- _ O
vaccinia -X- _ O
virus -X- _ O
derived -X- _ O
from -X- _ O
the -X- _ O
New -X- _ O
York -X- _ O
City -X- _ O
Board -X- _ O
of -X- _ O
Health -X- _ O
strain -X- _ O
elicited -X- _ O
protective -X- _ O
immune -X- _ O
responses -X- _ O
in -X- _ O
a -X- _ O
mouse -X- _ O
model -X- _ O
upon -X- _ O
inoculation -X- _ O
by -X- _ O
tail -X- _ O
scarification -X- _ O
, -X- _ O
we -X- _ O
investigated -X- _ O
whether -X- _ O
MVA -X- _ O
and -X- _ O
MVA -X- _ O
recombinants -X- _ O
can -X- _ O
elicit -X- _ O
protective -X- _ O
responses -X- _ O
following -X- _ O
percutaneous -X- _ O
administration -X- _ O
in -X- _ O
mouse -X- _ O
models. -X- _ O
Our -X- _ O
data -X- _ O
suggest -X- _ O
that -X- _ O
MVA -X- _ O
administered -X- _ O
by -X- _ O
percutaneous -X- _ O
inoculation -X- _ O
, -X- _ O
elicited -X- _ O
vaccinia-specific -X- _ O
antibody -X- _ O
responses -X- _ O
, -X- _ O
and -X- _ O
protected -X- _ O
mice -X- _ B-Patient
from -X- _ O
lethal -X- _ O
vaccinia -X- _ O
virus -X- _ O
challenge -X- _ O
, -X- _ O
at -X- _ O
levels -X- _ O
comparable -X- _ O
to -X- _ O
or -X- _ O
better -X- _ O
than -X- _ O
subcutaneous -X- _ O
or -X- _ O
intramuscular -X- _ O
inoculation. -X- _ O
High -X- _ B-Outcome
titers -X- _ I-Outcome
of -X- _ I-Outcome
specific -X- _ I-Outcome
neutralizing -X- _ I-Outcome
antibodies -X- _ I-Outcome
were -X- _ I-Outcome
elicited -X- _ I-Outcome
in -X- _ I-Outcome
mice -X- _ I-Outcome
inoculated -X- _ I-Outcome
with -X- _ I-Outcome
a -X- _ I-Outcome
recombinant -X- _ I-Outcome
MVA -X- _ I-Outcome
expressing -X- _ I-Outcome
the -X- _ I-Outcome
herpes -X- _ I-Outcome
simplex -X- _ I-Outcome
type -X- _ I-Outcome
2 -X- _ I-Outcome
glycoprotein -X- _ I-Outcome
D -X- _ I-Outcome
after -X- _ I-Outcome
scarification. -X- _ I-Outcome
Similarly -X- _ I-Outcome
, -X- _ I-Outcome
a -X- _ I-Outcome
recombinant -X- _ I-Outcome
MVA -X- _ I-Outcome
expressing -X- _ I-Outcome
the -X- _ I-Outcome
hemagglutinin -X- _ I-Outcome
of -X- _ I-Outcome
attenuated -X- _ I-Outcome
influenza -X- _ I-Outcome
virus -X- _ I-Outcome
rgA -X- _ I-Outcome
/ -X- _ I-Outcome
Viet -X- _ I-Outcome
Nam -X- _ I-Outcome
/ -X- _ I-Outcome
1203 -X- _ I-Outcome
/ -X- _ I-Outcome
2004 -X- _ I-Outcome
( -X- _ I-Outcome
H5N1 -X- _ I-Outcome
) -X- _ I-Outcome
elicited -X- _ I-Outcome
protective -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
when -X- _ I-Outcome
administered -X- _ I-Outcome
at -X- _ I-Outcome
low -X- _ I-Outcome
doses -X- _ I-Outcome
by -X- _ I-Outcome
scarification. -X- _ I-Outcome
Taken -X- _ I-Outcome
together -X- _ I-Outcome
, -X- _ I-Outcome
our -X- _ I-Outcome
data -X- _ I-Outcome
suggest -X- _ I-Outcome
that -X- _ I-Outcome
MVA -X- _ I-Outcome
and -X- _ I-Outcome
MVA-vectored -X- _ I-Outcome
vaccines -X- _ I-Outcome
inoculated -X- _ I-Outcome
by -X- _ I-Outcome
scarification -X- _ I-Outcome
can -X- _ I-Outcome
elicit -X- _ I-Outcome
protective -X- _ I-Outcome
immune -X- _ I-Outcome
responses -X- _ I-Outcome
that -X- _ I-Outcome
are -X- _ I-Outcome
comparable -X- _ I-Outcome
to -X- _ I-Outcome
subcutaneous -X- _ I-Outcome
vaccination -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
may -X- _ I-Outcome
allow -X- _ I-Outcome
for -X- _ I-Outcome
antigen -X- _ I-Outcome
sparing -X- _ I-Outcome
when -X- _ I-Outcome
vaccine -X- _ I-Outcome
supply -X- _ I-Outcome
is -X- _ I-Outcome
limited -X- _ I-Outcome
. -X- _ I-Outcome

